Supplementary data: Cost–effectiveness of concurrent radiation with cetuximab or chemotherapy in older patients with oropharyngeal cancer

These are peer-reviewed supplementary materials for the article 'Cost–effectiveness of concurrent radiation with cetuximab or chemotherapy in older patients with oropharyngeal cancer' published in the Journal of Comparative Effectiveness Research.Appendix Table 1: Matching variables for each comparisonAppendix Table 2: Censoring rates at 5 years, stratified by treatment groups and diagnosis periodAppendix Table 3: Characteristics of the matched sample comparing the RT and CRT groups in Cohort IAppendix Table 4: Characteristics of the matched sample comparing the RT and CRT groups in Cohort IIAppendix Table 5: Characteristics of the matched sample comparing the RT and cetuximab-RT groups in Cohort IIAppendix Table 6: Characteristics of the matched sample comparing the CRT and cetuximab-RT groups in Cohort IIAim: To assess the cost–effectiveness of definitive therapies for nonmetastatic oropharyngeal cancer (OPC). Materials & methods: Using the Surveillance, Epidemiology and End Results-Medicare dataset, patients diagnosed between 2000 and 2011 were identified. The cost–effectiveness of chemoradiation (CRT) versus radiotherapy (RT), cetuximab plus RT (cetuximab-RT) versus RT and cetuximab-RT versus CRT were estimated. Results: The incremental cost–effectiveness ratio for CRT compared with RT from 2000 to 2005 was US$56,650 (95% CI: US$4,522–$288,688) per additional year of survival. CRT was dominated by RT from 2006 to 2011. Cetuximab-RT was dominated by RT and CRT. Conclusion: CRT had a favorable value from 2000 to 2005 but was dominated by RT from 2006 to 2011. The value of cetuximab-RT compared with RT/CRT was not favorable with similar/inferior survival and substantial incremental costs.

本数据集为发表于《比较疗效研究杂志》之文章《同步放化疗与单用化疗在老年口腔癌患者中的成本效益分析》的同行评审补充材料。附录表1：各比较组的匹配变量；附录表2：按治疗组和诊断时期分层，5年内的截尾率；附录表3：第I队列中RT与CRT组的匹配样本特征；附录表4：第II队列中RT与CRT组的匹配样本特征；附录表5：第II队列中RT与cetuximab-RT组的匹配样本特征；附录表6：第IIA队列中CRT与cetuximab-RT组的匹配样本特征。研究目的：评估非转移性口腔癌（OPC）确定性治疗方案的经济学效益。研究方法：利用美国国家癌症监测、流行病学和结果-医疗保险数据库，确定2000年至2011年间诊断的患者。评估了化疗放疗（CRT）与放疗（RT）、西妥昔单抗联合放疗（cetuximab-RT）与RT、cetuximab-RT与CRT的经济学效益。结果：2000年至2005年间，与RT相比，CRT的增量成本效益比为每增加一年生存期美国美元56,650（95%置信区间：4,522–$288,688）。2006年至2011年间，CRT被RT所超越。cetuximab-RT在RT和CRT面前处于劣势。结论：2000年至2005年间，CRT具有可取的经济学价值，但自2006年至2011年被RT超越。与RT/CRT相比，cetuximab-RT的经济学价值并不理想，其生存期相似或较差，且增量成本显著。